India (National)
Not enough data
Varsha's coverage indicates a focus on Indian stock market developments, particularly in the pharmaceutical, chemical, and logistics sectors. She frequently cites data and provides investment analysis. To reach out effectively to Varsha Chandnani, consider offering data-driven insights into the performance of companies within these industries or providing expert analysis on market trends and their impact on specific businesses.
Given her focus on investment analysis and citing data extensively, she may be interested in exclusive access to financial reports or insider perspectives that can provide deeper insights into company performance or industry trends that are relevant to her coverage areas.
As Varsha has a national geographic focus (India), pitches should take this into account by emphasizing how the information provided is specifically relevant to developments within India's stock markets.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Anas Ali, Varsha Chandnani
Vohra's track record at Cipla makes him a strategic fit for Cohance, which is itself navigating a similar transition, from volume manufacturing toward value-based partnerships with innovator and specialty pharma clients.
By: Anas Ali, Varsha Chandnani
The stellar numbers for Gland Pharma were largely driven by a combination of factors, including strong US traction led by new launches.
Shares of Gland Pharmaceuticals Ltd. are buzzing in trade on Monday, rallying as much as 13% on the back of a stellar fourth quarter earnings.
By: Anas Ali, Varsha Chandnani
Developers had pushed back hard, citing fears of a domestic solar cell shortage, higher procurement costs and execution delays.
By: Anas Ali, Varsha Chandnani
The solar sector will be in focus on Tuesday's trade following a significant policy decision from the Ministry of New and Renewable Energy that saw
By: Yukta Baid, Varsha Chandnani
Zaynich, approved for complicated urinary tract infections and pyelonephritis, is aimed at treating infections caused by drug-resistant bacteria — an area where doctors globally are facing shrinking treatment options as antimicrobial resistance rises.
By: Nikita Prasad, Varsha Chandnani
Cipla Share Price Gains 4% As Citi Maintains Bullish Stance For 90-Day Momentum: Check Target Price
By: Nikita Prasad, Varsha Chandnani
Shares of Cipla Ltd. gained over 4% on Monday, June 22, after global brokerage Citi maintained a bullish stance on the pharmaceutical major, initiating a 90-day positive catalyst watch.
By: Varsha Chandnani, Yukta Baid
According to media reports, the regulator has communicated through the Indian Drug Manufacturers' Association (IDMA) to identify companies that can immediately supply ifosfamide injection, a generic chemotherapy drug used in the treatment of several cancers, including testicular, bladder and lung cancer.
By: Varsha Chandnani, Yukta Baid
Shares of Indian pharmaceutical companies are likely to remain in focus after reports that the US Food and Drug Administration (US FDA) has reached
